FBRX vs NUVL vs PRAX vs TARS

For growth investors, Tarsus Pharmaceuticals, Inc.

(TARS) is the stronger pick with 146. 7% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Forte Biosciences, Inc. (FBRX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nuvalent, Inc.

(NUVL) delivered a total return of +461. 5%, compared to -97. 0% for Forte Biosciences, Inc. (FBRX). Over 10 years, the gap is even starker: NUVL returned +461. 5% versus FBRX's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Tarsus Pharmaceuticals, Inc.

(TARS) is the lower-risk stock at 0. 66β versus Forte Biosciences, Inc. 's 1. 47β — meaning FBRX is approximately 121% more volatile than TARS relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 27% for Tarsus Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Tarsus Pharmaceuticals, Inc.

(TARS) is pulling ahead at 146. 7% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Forte Biosciences, Inc. grew EPS 51. 2% year-over-year, compared to -48. 9% for Nuvalent, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Forte Biosciences, Inc.

(FBRX) is the more profitable company, earning 0. 0% net margin versus -14. 7% for Tarsus Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FBRX leads at 0. 0% versus -15. 7% for TARS. At the gross margin level — before operating expenses — TARS leads at 93. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Tarsus Pharmaceuticals, Inc.

(TARS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), +197. 4% 10Y return). Both have compounded well over 10 years (TARS: +197. 4%, FBRX: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: FBRX is a small-cap quality compounder stock; NUVL is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; TARS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.